Phosphate & Kidney Stones
Public ClinicalTrials.gov record NCT07903961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of Low-Dose Neutral Phosphate Supplementation for Reducing Urine Calcium and Supersaturation in Patients With Recurrent Calcium Oxalate Kidney Stones and Hypophosphatemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Kidney stones are common and often come back. One reason may be that some people with calcium stones have low phosphate levels in the blood and lose too much phosphate through the kidneys. They may also have high calcium in the urine, which raises the chance of forming stones. In older studies, high doses of phosphate supplements lowered urine calcium and appeared to reduce stone formation, but they sometimes caused stomach and bowel side effects, and phosphate is no longer used for stone prevention. This small pilot study will test a much lower dose of neutral phosphate (250 mg twice daily) for 2 weeks in adults with recurrent calcium oxalate kidney stones, high urine calcium, and low blood phosphate. Participants will collect a 24-hour urine sample and have blood drawn before and after the 2-week period. The study will look at whether the low dose reduces urine calcium and the risk of stone formation in urine. The results will help decide whether a larger study is warranted.
Study identification
- NCT ID
- NCT07903961
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 5 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2026 (Estimated)
- Primary completion
- Dec 31, 2027 (Estimated)
- Completion
- Jan 31, 2028 (Estimated)
- Last update posted
- Oct 29, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | 60637 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07903961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2026 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07903961 live on ClinicalTrials.gov.